Littleton, CO, March 20, 2011 --(PR.com
)-- Novus Biologicals announced today the release of three new rabbit polyclonal antibodies to important histone demethylase proteins: JMJD2C (Catalog# NBP1-49600), JMJD1A (Catalog# NBP1-49601), and JMJD2A (Catalog# NBP1-49602).
All three of these new antibodies cross-react with human and mouse proteins, and are useful for Western blot, immunohistochemistry on paraffin tissues, and fluorescent immunocytochemistry.
JMJD2C and JMJD2A are members of the JHDM3 histone demethylase family. Specifically these proteins demethylate trimethyl 'Lys-9' and 'Lys-36' residues of histone H3, while generating formaldehyde and succinate byproducts. JMJD1A is a member of the JHDM2 histone demethylase family, and preferentially demethylates mono- and dimethylated H3 'Lys-9' residue but has weak or no activity on trimethylated H3 'Lys-9'. Together, these three proteins hold an integral role in coding histones with covalent tail modifications, thereby affecting chromatin structure and the subsequent regulation of gene expression.
Novus Biologicals provides a broad catalog of chromatin research reagents, as well as specific Histone H3 antibodies. All products are 100% guaranteed to work in the species and applications listed on the datasheet, and the Innovator's Reward Program supports researchers testing of additional species and applications.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.